Guidelines to the Intron A [interferon alfa-2b] Health Management Program II: A Nursing Support Program for Patients With High-Risk Melanoma Receiving High Dose Intron A Therapy
Latest Information Update: 10 May 2022
At a glance
- Drugs Interferon alpha-2b (Primary) ; Interferon alpha-2b (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.; Schering-Plough
- 10 Sep 2012 Planned end date changed from 1 Sep 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jul 2012 Planned end date changed from 1 Jul 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.